Pharmacology of autism

Clinical Neuroscience Research

Volumn 6, Issue 3-4, 2006, Pages 179-188

  McDougle, Christopher J ^a   Stigler, Kimberly A ^a   Erickson, Craig A ^a   Posey, David J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Autism; Dopamine; Glutamate; Psychopharmacology; Serotonin

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; CYCLOSERINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANGER; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; AUTISM; AUTOMUTILATION; BEHAVIOR; BODY WEIGHT DISORDER; CLINICAL TRIAL; COMPULSION; DECREASED APPETITE; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; ECHOLALIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; OPEN STUDY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RITUAL; SEIZURE; SIDE EFFECT; SOCIAL DISABILITY; SOMNOLENCE; STEREOTYPY; SYMPTOM; TARDIVE DYSKINESIA; TIC; UNSPECIFIED SIDE EFFECT;

EID: 33749995213     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2006.06.012     Document Type: Article

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Press; 1994.
2. Greenhill L., Beyer D.H., Finkleson J., Shaffer D., Biederman J., Conners C.K., Gillberg C., Huss M., Jensen P., Kennedy J.L., Klein R., Rapoport J., Sagvolden T., Spencer T., Swanson J.M., and Volkow N. Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord 6 (2002) S89-S100
3. Campbell M. Pharmacotherapy in early infantile autism. Biol Psychiatry 10 (1975) 399-423
4. Aman M.G. Stimulant drug effects in developmental disorders and hyperactivity-toward a resolution of disparate findings. J Autism Dev Disord 12 (1982) 385-398
5. Quintana H., Birmaher B., Stedge D., Lennon S., Freed J., Bridge J., and Greenhill L. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25 (1995) 283-294
6. Handen B.L., Johnson C.R., and Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30 (2000) 245-255
7. Stigler K.A., Desmond L.A., Posey D.J., Wiegand R.E., and McDougle C.J. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14 (2004) 49-56
8. Research Units on Pediatric Psychopharmacology Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-74.
9. Di Martino A., Melis G., Cianchetti C., and Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 14 (2004) 207-218
10. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., Benson R.S., Bukstein O., Kinlan J., McClellan J., Rue D., Shaw J.A., and Stock S. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 (2001) 26S-49S
11. Jaselskis C.A., Cook Jr. E.H., Fletcher K.E., and Leventhal B.L. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12 (1992) 322-327
12. Fankhauser M.P., Karumanchi V.C., German M.L., Yates A., and Karumanchi S.D. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53 (1992) 77-82
13. Posey D.J., Puntney J.I., Sasher T.M., Kem D.L., and McDougle C.J. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14 (2004) 233-241
14. Kanner L. Autistic disturbances of affective contact. Nerv Child 2 (1943) 217-250
15. McDougle C.J., Kresch L.E., Goodman W.K., Naylor S.T., Volkmar F.R., Cohen D.J., and Price L.H. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152 (1995) 772-777
16. McDougle C.J., Posey D.J., and Potenza M.N. Neurobiology of serotonin function in autism. In: Hollander E. (Ed). Autism spectrum disorders (2003), Marcel Dekker, Inc., New York, NY 199-220
17. McDougle C.J. Repetitive thoughts and behavior in pervasive developmental disorders: phenomenology and pharmacotherapy. In: Schopler E., Mesibov G.B., and Kunce L.J. (Eds). Asperger syndrome or high functioning autism? current issues in autism series (1998), Plenum Publishing Corporation, New York, NY 293-316
18. McDougle C.J., Kresch L.E., and Posey D.J. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30 (2000) 427-435
19. Gordon C.T., State R.C., Nelson J.E., Hamburger S.D., and Rapoport J.L. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50 (1993) 441-447
20. Remington G., Sloman L., Konstantareas M., Parker K., and Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 21 (2001) 440-444
21. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., and Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 (1996) 1001-1008
22. Sugie Y., Sugie H., Fukuda T., Ito M., Sasada Y., Nakabayashi M., Fukashiro K., and Ohzeki T. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord 35 (2005) 377-385
23. Buchsbaum M.S., Hollander E., Haznedar M.M., Tang C., Spiegel-Cohen J., Wei T.C., Solimando A., Buchsbaum B.R., Robins D., Bienstock C., Cartwright C., and Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 4 (2001) 119-125
24. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., and Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 (2005) 582-589
25. McBride P.A., Anderson G.M., Hertzig M.E., Snow M.E., Thompson S.M., Khait V.D., Shapiro T., and Cohen D.J. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 37 (1998) 767-776
26. Chugani D.C., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., and Chugani H.T. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45 (1999) 287-295
27. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., Arnold L.E., Posey D.J., Martin A., Ghuman J.K., Shah B., Chuang S.Z., Swiezy N.B., Gonzalez N.M., Hollway J., Koenig K., McGough J.J., Ritz L., and Vitiello B. Risperidone for the core symptom domains of autism: results from the RUPP Autism Network Study. Am J Psychiatry 162 (2005) 1142-1148
28. Campbell M., Anderson L.T., Meier M., Cohen I.L., Small A.M., Samit C., and Sachar E.J. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17 (1978) 640-655
29. Anderson L.T., Campbell M., Adams P., Small A.M., Perry R., and Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19 (1989) 227-239
30. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative symptom scale for schizophrenia. Psychiatry Res. 23 (1987) 99-110
31. Fisman S., and Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 6 (1996) 177-190
32. Baldessarini R.J., and Frankenburg F.R. Clozapine: a novel antipsychotic agent. N Engl J Med 14 (1991) 746-754
33. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., and Janssen P.A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247 (1988) 661-670
34. McDougle C.J., Holmes J.P., Carlson D.C., Pelton G.H., Cohen D.J., and Price L.H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55 (1998) 633-641
35. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321.
36. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., and Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) 634-641
37. RUPP Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after six months. Am J Psychiatry 2005;162:1361-69.
38. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., and Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124 (1996) 87-94
39. Potenza M.N., Holmes J.P., Kanes S.J., and McDougle C.J. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19 (1999) 37-44
40. Arnt J., and Skarsfeldt M. Do novel antipsychotics have similar pharmacological characteristics: a review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
41. Corson A.H., Barkenbus J.E., Posey D.J., Stigler K.A., and McDougle C.J. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65 (2004) 1531-1536
42. Tandon R., Harrigan E., and Zorn S.H. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4 (1997) 159-177
43. McDougle C.J., Kem D.L., and Posey D.J. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41 (2002) 921-927
44. Psychopharmacological Drugs Advisory Committee. FDA Background Document on Zeldox (PDAC 0700.M01). Rockville, MD. Food and Drug Administration. 2000.
45. 2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
46. Stigler K.A., Posey D.J., and McDougle C.J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14 (2004) 455-463
47. Carlsson M.L. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy. J Neural Transm 105 (1998) 525-535
48. Belsito K.M., Law P.A., Kirk K.S., Landa R.J., and Zimmerman A.W. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31 (2001) 175-181
49. King B.H., Wright D.M., Handen B.L., Sikich L., Zimmerman A.W., McMahon W., Cantwell E., Davanzo P.A., Dourish C.T., Dykens E.M., Hooper S.R., Jaselskis C.A., Leventhal B.L., Levitt J., Lord C., Lubetsky M.J., Myers S.M., Ozonoff S., Shah B.G., Snape M., Shernoff E.W., Williamson K., and Cook Jr. E.H. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40 (2001) 658-665
50. Posey D.J., Kem D.L., Swiezy N.B., Sweeten T.L., Wiegand R.E., and McDougle C.J. A pilot study of d-cycloserine in autistic disorder. Am J Psychiatry 161 (2004) 2115-2117